Cargando…

Hepatotoxicity in Advanced Lung Adenocarcinoma: A Retrospective Study of 2108 Cases

The study aimed to identify the risk factors and frequency of hepatotoxicity in patients with advanced lung adenocarcinoma. Liver function tests were documented in 2108 patients with advanced (IIIB/IV) lung adenocarcinoma at a single institution who received first line platinum-based doublet chemoth...

Descripción completa

Detalles Bibliográficos
Autores principales:	Qian, Jie, Zhang, Xueyan, Zhang, Bo, Gu, Ping, Wang, Lin, Han, Baohui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2018
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5950590/ https://www.ncbi.nlm.nih.gov/pubmed/29760799 http://dx.doi.org/10.7150/jca.24217

Ejemplares similares

Tyrosine Kinase Inhibitor-Related Hepatotoxicity in Patients with Advanced Lung Adenocarcinoma: A Real-World Retrospective Study
por: Qian, Jie, et al.
Publicado: (2020)

COLLABORATION AGREEMENT KE2108/EN
por: THE EUROPEAN ORGANIZATION FOR NUCLEAR RESEARCH, CERN, et al.
Publicado: (2013)

2108. Comparison of Voriconazole vs. Itraconazole in the Treatment of Histoplasmosis – A Retrospective Analysis
por: Hendrix, Michael J, et al.
Publicado: (2019)

Infectious Disease Prevention and Control: Remembering 1908 and Imagining 2108
por: Brunham, Robert C.
Publicado: (2009)

Prognosis of EGFR-mutant advanced lung adenocarcinoma patients with different intrathoracic metastatic patterns
por: Hu, Fang, et al.
Publicado: (2019)

MDC and BLC are independently associated with the significant risk of early stage lung adenocarcinoma
por: Zhang, Yanwei, et al.
Publicado: (2016)

Analysis of the clinical effect of osimertinib on 90 cases with advanced lung adenocarcinoma
por: Gao, Zhiqiang, et al.
Publicado: (2020)

Akt kinase LANCL2 functions as a key driver in EGFR-mutant lung adenocarcinoma tumorigenesis
por: Lou, Yuqing, et al.
Publicado: (2021)

2108. Perfluorocarbon Omniphobic Treatment Prevents Bacterial Colonization of Urinary Catheter in a Rat Model
por: Badv, Maryam, et al.
Publicado: (2018)

Epidemiological characteristics and distribution of congenital thumb duplication in south China: An analysis of 2,300 thumbs in 2,108 children
por: Wu, JianPing, et al.
Publicado: (2022)

Comparison of outcomes of tyrosine kinase inhibitor in first- or second-line therapy for advanced non-small-cell lung cancer patients with sensitive EGFR mutations
por: Xu, Jianlin, et al.
Publicado: (2016)

Pathologic subtype-defined prognosis is dependent on both tumor stage and status of oncogenic driver mutations in lung adenocarcinoma
por: Dong, Yu, et al.
Publicado: (2017)

CXCL9 as a Prognostic Inflammatory Marker in Early-Stage Lung Adenocarcinoma Patients
por: Zhang, Yanwei, et al.
Publicado: (2020)

Molecular profiling identifies prognostic markers of stage IA lung adenocarcinoma
por: Zhang, Jie, et al.
Publicado: (2017)

2108 Factors associated with dual use of VA and civilian healthcare among U.S. National Guard and Reserve soldiers
por: Vest, Bonnie M., et al.
Publicado: (2018)

2108. In-vitro Activity of Five Novel Anti-Fungal Compounds Against Thirty-Two Strains of Talaromyces marneffei
por: Barwatt, Joseph, et al.
Publicado: (2023)

Serum TNFRII: A promising biomarker for predicting the risk of subcentimetre lung adenocarcinoma
por: Hu, Minjuan, et al.
Publicado: (2020)

Draft Genome Sequence of Bacillus subtilis subsp. natto Strain CGMCC 2108, a High Producer of Poly-γ-Glutamic Acid
por: Tan, Siyuan, et al.
Publicado: (2016)

PB2108: PREVALENCE AND CLINICAL IMPLICATIONS OF CYCLIN D1 POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA IN CHINA
por: Liang, X., et al.
Publicado: (2022)

Efficacy of EGFR-TKI Plus Chemotherapy or Monotherapy as First-Line Treatment for Advanced EGFR-Mutant Lung Adenocarcinoma Patients With Co-Mutations
por: Yang, Zhengyu, et al.
Publicado: (2021)

Association of XPC Polymorphisms and Lung Cancer Risk: A Meta-Analysis
por: Jin, Bo, et al.
Publicado: (2014)

PReS-FINAL-2108: Long-term outcome of 114 adult JIA patients in a non-pediatric rheumatology institute in Japan
por: Miyamae, T, et al.
Publicado: (2013)

The clinicopathological and molecular characteristics of resected EGFR‐mutant lung adenocarcinoma
por: Zhou, Wensheng, et al.
Publicado: (2022)

Hepatotoxicity of immune checkpoint inhibitors: What is Currently Known
por: Zheng, Caiyun, et al.
Publicado: (2023)

Advances in the Study of the Potential Hepatotoxic Components and Mechanism of Polygonum multiflorum
por: Yu, He-Shui, et al.
Publicado: (2020)

USP22 promotes development of lung adenocarcinoma through ubiquitination and immunosuppression
por: Han, Bing, et al.
Publicado: (2020)

Antigen presentation of the Oct4 and Sox2 peptides by CD154-activated B lymphocytes enhances the killing effect of cytotoxic T lymphocytes on tumor stem-like cells derived from cisplatin-resistant lung cancer cells
por: Zhang, Xueyan, et al.
Publicado: (2018)

Phenotypic and clinical characterization of low density neutrophils in patients with advanced lung adenocarcinoma
por: Liu, Yangyang, et al.
Publicado: (2017)

A retrospective analysis in patients with EGFR-mutant lung adenocarcinoma: is EGFR mutation associated with a higher incidence of brain metastasis?
por: Han, Guang, et al.
Publicado: (2016)

Long non‐coding RNA‐CTD‐2108O9.1 represses breast cancer metastasis by influencing leukemia inhibitory factor receptor
por: Wang, Mozhi, et al.
Publicado: (2018)

The Survival Benefit for Optimal Glycemic Control in Advanced Non-Small Cell Lung Cancer Patients With Preexisting Diabetes Mellitus
por: Qian, Jie, et al.
Publicado: (2021)

Two-stage induced differentiation of OCT4(+)/Nanog(+) stem-like cells in lung adenocarcinoma
por: Li, Rong, et al.
Publicado: (2016)

Afatinib 30 mg in the treatment of common and uncommon EGFR-mutated advanced lung adenocarcinomas: a retrospective, single-center, longitudinal study
por: Qian, Jie, et al.
Publicado: (2022)

Pembrolizumab Alone or Combined With Chemotherapy in Advanced NSCLC With PD-L1 ≥50%: Results of a Retrospective Study
por: Chen, Ya, et al.
Publicado: (2021)

Rationale and design of a phase II trial of dacomitinib in advanced non-small cell lung cancer patients with uncommon epidermal growth factor receptor mutations: a prospective and single arm study (DANCE study)
por: Zhang, Bo, et al.
Publicado: (2022)

Hepatotoxic potential of asarones: in vitro evaluation of hepatotoxicity and quantitative determination in herbal products
por: Patel, Dhavalkumar N., et al.
Publicado: (2015)

EGFR mutation, smoking, and gender in advanced lung adenocarcinoma
por: Tseng, Chien-Hua, et al.
Publicado: (2017)

Ceftriaxone-induced hepatotoxicity in patients with common medical infections in Qatar: A retrospective study
por: Barman, Manish, et al.
Publicado: (2022)

Case Report: Stevens-Johnson Syndrome and Hepatotoxicity Induced by Osimertinib Sequential to Pembrolizumab in a Patient With EGFR-Mutated Lung Adenocarcinoma
por: Gianni, Caterina, et al.
Publicado: (2021)

Impact of capillary invasion on the prognosis of gastric adenocarcinoma patients: A retrospective cohort study
por: Xue, Lian, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_kppjkdh60mhscjib700ulguhs0